|
| Status |
Public on Jun 01, 2012 |
| Title |
LM227 |
| Sample type |
RNA |
| |
|
| Source name |
BATTLE_trial_core biopsy_chemorefractory non-small cell lung cancer
|
| Organism |
Homo sapiens |
| Characteristics |
egfr mutation: WT
kras mutation: Mutant
egfr index: 1.13
histology-iw revised: Adenocarcinoma
egfr-iw type: No
kras-iw mutation (yes/no): Yes
codon kras mut: 12
type of kras mut: GGT12GAT
base change: G to A
transition/transversion: Transition
type kras aa change: ASP
glyc replaced by c, d, v and a: D
aa change cys vs. other: Other
gender: Male
race: White
stage_at_diagnosis: IIIB
prior_tx_for_mets: 2
smoking_status: Former
biopsy site (grouped): 1: Lung
treatment: sorafenib
markergroup: 2
8-week disease control (1=yes, 0=no): 1
randomization_date: 2008-05-29
date_of_progression: 4-Mar-09
pfsc (1=progressed; 0=not progressed): 1
pfsm (month): 9.1663
|
| Treatment protocol |
Samples were OCT-embedded and frozen before RNA extraction
|
| Growth protocol |
Core biopsies from patients included in the Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE)
|
| Extracted molecule |
total RNA |
| Extraction protocol |
RNA was extracted and purified from OCT-embedded tissue using the RNeasy Mini Kit (Qiagen) including on-column DNase (Qiagen) digestion as described by the manufacturer's protocol.
|
| Label |
biotin
|
| Label protocol |
WT-Ovation™ Pico products (NuGEN) are labeled using the FL-Ovation™ cDNA Biotin Module V2 (NuGEN). Each labeled cRNA targets are synthesized according to manufacturer's protocols.
|
| |
|
| Hybridization protocol |
Hybridization mixtures were prepared according to Affymetrix procedures to accommodate 5 μg of cDNA targets from NuGEN amplification. Human Gene 1.ST platform were hybridized, revealed and washed according to the Affymetrix protocol.
|
| Scan protocol |
Gene chips were scanned using a 7 G scanner (Affymetrix) and images (DAT files) were converted to CEL files using GCOS software (Affymetrix).
|
| Description |
LM001_525_AGE_1_LM227_10_08_08
Inclusion number in the clinical trial : 175
|
| Data processing |
Raw data of microarrays were processed using quantile normalization and RMA algorithm (RMAExpress); expression values were log2 transformed
|
| |
|
| Submission date |
Feb 17, 2011 |
| Last update date |
Jun 01, 2012 |
| Contact name |
Pierre Saintigny |
| E-mail(s) |
psaintig@mdanderson.org
|
| Organization name |
The University of Texas M.D. Anderson Cancer Center
|
| Department |
Thoracic / Head and Neck Medical Oncology
|
| Street address |
1515 Holcombe
|
| City |
Houston |
| ZIP/Postal code |
77030 |
| Country |
USA |
| |
|
| Platform ID |
GPL6244 |
| Series (4)
|
| GSE27389 |
Substitutions in the KRas oncogene determine protein behavior: Implications for signaling and clinical outcome. |
| GSE31428 |
Final efficacy and biomarker analysis of the sorafenib arm of the BATTLE (Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination) trial |
| GSE31852 |
An EGFR-mutation signature reveals features of the EGFR-dependent phenotype and identifies MACC1 as an EGFR-associated regulator of MET. |
| GSE33072 |
An epithelial-mesenchymal transition (EMT) gene signature predicts resistance to erlotinib and PI3K pathway inhibitors and identifies Axl as a novel EMT marker in non-small cell lung cancer. |
|
Less...
More...